Known targets — ChEMBL curated mechanism
ACHECHRM1CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNG
The experimentally established mechanism targets of Iodide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.48 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | HPGD | P15428 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.45 |
| ▸ | CASP7 | P55210 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29565104 | 0.97 | — | — | |
| SCHEMBL71324 | 0.97 | — | — | |
| Bromide SCHEMBL27523623 | 0.95 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| Hydrochloric Acid SCHEMBL6679000 | 0.95 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| Methane SCHEMBL28845870 | 0.95 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL7541993 | 0.95 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| Ammonia Solution, Strong SCHEMBL27579641 | 0.95 | CYP3A4 (0.57) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL13518495 | 0.86 | CYP3A4 (0.50) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL28029914 | 0.85 | CYP1A2 (0.46) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E | |
| SCHEMBL27588238 | 0.84 | CYP3A4 (0.48) | CYP3A4CYP1A2CYP2C9CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1844004-B1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LTD (GB) | 2009-06-24 | — | — | EP | disclosed |
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | ARROW THERAPEUTICS LIMITED (GB) | 2008-05-15 | — | — | US | disclosed |
| EP-1844004-A1 | QUINAZOLINE DERIVATES AS ANTIVIRAL AGENTS | Arrow Therapeutics Limited (GB) | 2007-10-17 | — | — | EP | disclosed |
| WO-2006079833-A1 | QUINAZOLINE DERIVATIVES AS ANTIVIRAL AGENTS | ARROW THERAPEUTICS LIMITED (GB) | 2006-08-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080114008-A1 | Quinazoline Derivatives as Antiviral Agents | IFNAR1, C5, EIF2AK2 | CYP3A4 122/4885CYP1A2 313/4885CYP2C9 336/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.